ExSight Ventures
Status
ACTIVE
Global HQ
New York, United States
Countries of investment
- USA Canada
Investment stages
- Seed
- Series A
Industries
- Biotechnology
- Health Tech
- AI
About
ExSight Ventures is a mission-focused venture capital firm investing in early-stage ophthalmic solutions, led by retinal surgeons to bridge the funding gap in life sciences.
ExSight Ventures is a mission-focused venture capital firm investing in early-stage ophthalmic solutions, led by retinal surgeons to bridge the funding gap in life sciences.
Investment Thesis
ExSight Ventures invests in early stage ophthalmic diagnostic and treatment solutions to address the lack of early stage funding available to life science companies, relying on deep domain expertise in ophthalmology.
Manager's Experience
With a robust track record in venture capital, the fund manager has executed over 50 deals primarily in the technology and healthcare sectors. Their investment strategy emphasizes a data-driven approach, focusing on early to growth-stage opportunities across North America and Europe. Notable exits from their portfolio have significantly contributed to their reputation in the industry. Leveraging deep operational insights, the manager actively identifies thematic trends that drive innovation and value creation.
ExSight Ventures Contacts Information
Primary contact
Team
James Murray
Portfolio
ELIOS Vision
Re-Vana Therapeutics
Horizon Surgical Systems
DTx Pharma (acquired by Novartis)
Trefoil Therapeutics
Qura
Envision Diagnostics
2C Tech Corporation
ONL Therapeutics
RetroSense Therapeutics (acquired by Allergan)
LensGen
Valitor Bio
Novai.